Mme Docteur CAROLINE CHARPIN

Thèses universitaires

• Nouveaux auto-anticorps dans la polyarthrite rhumatoïde

  2011
  Biologie, Spécialité Immunologie🎓 Aix-Marseille 2

  Direction : Isabelle Auger

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey

  2024

  ArticleHuman Vaccines & Immunotherapeutics

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

• Altered muscle membrane potential and redox status differentiates two subgroups of patients with chronic fatigue syndrome

  2020

  ArticleJournal of Translational Medicine

• Maximal handgrip strength can predict maximal physical performance in patients with chronic fatigue

  2020

  ArticleClinical Biomechanics

• Single Injection of High Volume of Autologous Pure PRP Provides a Significant Improvement in Knee Osteoarthritis: A Prospective Routine Care Study

  2019

  ArticleInternational Journal of Molecular Sciences

• New autoantibodies in early rheumatoid arthritis

  2013

  ArticleArthritis Research and Therapy

• New autoantibodies in early rheumatoid arthritis.

  2013

  ArticleArthritis Research and Therapy

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation des cabinets

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CABINET DU DR CAROLINE CHARPIN

  HOPITAL SAINT JOSEPH, SCE DE RHUMATOLOGIE — 26 BOULEVARD DE LOUVAIN, 13008 Marseille

  Libéral
  86 m86 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• CABINET DU DR CAROLINE CHARPIN

  HOPITAL EUROPEEN — 6 RUE DESIREE CLARY, 13003 Marseille

  ☎ 0413427000Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients

  Arthritis research & therapy · 2009

  📚 83 citations🎯 RCR 2.69Top 19% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Introduction Reactivation of hepatitis B virus (HBV) infection in patients with past infection has been described in 5% to 10% of individuals undergoing immunosuppressive therapies. No data are available to date on the outcome of patients treated by tumour necrosis factor-alpha (TNFα) inhibitors for chronic arthritis with a serological pattern of past HBV infection. The aim of our study was to monitor HBV markers in HBV surface antigen (HBsAg)-negative/anti-HBcAb-positive patients treated with a TNFα inhibitor for inflammatory arthritides. Methods Twenty-one HBsAg-negative/anti-HBcAb-positive patients were included. HBV serological patterns were compared with those determined before starting TNFα inhibitors. Serum HBV DNA testing by polymerase chain reaction was additionally performed. Spearman correlation analysis was used and P < 0.05 was chosen as the significance threshold. Results Before starting therapy, mean anti-HBsAb titre was 725 IU/L, no patient had an anti-HBsAb titre <10 IU/L, and 18 patients had an anti-HBsAb >100 IU/L. At a mean time of 27.2 months following therapy introduction, mean anti-HBsAb titre was 675 IU/L and anti-HBsAb titre remained >100 IU/L in 17 patients. There was a strong correlation between the first and second anti-HBsAb titres (r = 0.98, P = 0.013). Moreover, no patient had an anti-HBsAb titre below 10 IU/L or HBV reactivation (HBsAg seroreversion or positive HBV DNA detection). However, the anti-HBsAb titre decreased by more than 30% in 6 patients. The mean anti-HBsAb titre at baseline was significantly lower (P = 0.006) and the mean duration of anti-TNFα therapy, although non-significant (P = 0.09), was longer in these six patients as compared to patients without a decrease in anti-HBsAb titre. Conclusions Anti-TNFα treatments are likely to be safe in patients with past hepatitis B serological pattern. However, the significant decrease of anti-HBsAb titre observed in a proportion of patients deserves HBV virological follow-up in these patients, especially in those with a low anti-HBsAb titre at baseline.

• 2

  HLA-DRB1 genotypes and the risk of developing anti citrullinated protein antibody (ACPA) positive rheumatoid arthritis

  PloS one · 2013

  📚 51 citations🎯 RCR 1.73🔓 Open Access📄 PDF gratuit ↗
• 3

  Single Injection of High Volume of Autologous Pure PRP Provides a Significant Improvement in Knee Osteoarthritis: A Prospective Routine Care Study

  International journal of molecular sciences · 2019

  📚 42 citations🎯 RCR 3.33Top 14% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Background: Evidence is growing regarding the ability of platelet-rich plasma (PRP) injections to enhance functional capacity and alleviate pain in knee osteoarthritis (OA). However, heterogeneity in common practice regarding PRP preparation and biological content makes the initiation of this activity in a hospital complex. The aim of this study was to document the efficacy of a single PRP injection to treat knee OA and validate a routine care procedure. Methods: Fifty-seven patients with symptomatic knee OA received a single injection of large volume of very pure PRP. They were assessed at baseline and after one, three and six months, by measuring Knee Injury and Osteoarthritis Score (KOOS), Observed Pain after a 50-foot walk test and Visual Analog Scale (VAS) assessments. Magnetic Resonance Imaging (MRI) analysis was performed at baseline and six months after the procedure. The objective was to recover 50% of responders three months after the procedure using OMERACT-OARSI criteria. Results: A single administration of high volume pure PRP provided significant clinical benefit for 84.2% of the responders, three months after the procedure. The KOOS total score significantly increased from 43.5 ± 14.3 to 66.4 ± 21.7 six months after the procedure (p < 0.001). Pain also significantly decreased from 37.5 ± 25.1 to 12.9 ± 20.9 (p < 0.001). No difference was observed on MRI parameters. Conclusion: A single injection of large volume of very pure PRP is associated with significant functional improvement and pain relief, allowing initiation of daily PRP injection within our hospital.

Publications scientifiques (12) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis

  Collection2021figshare

  Abstract Introduction BRAF (v raf murine sarcoma viral oncogene homologue B1) is a serine-threonine kinase involved in the mitogen-activated protein kinase (MAPK) signalling pathway, known to be implicated in the product

• Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis

  Collection2021figshare

  Abstract Introduction BRAF (v raf murine sarcoma viral oncogene homologue B1) is a serine-threonine kinase involved in the mitogen-activated protein kinase (MAPK) signalling pathway, known to be implicated in the product

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche